Search

Your search keyword '"Assouline, David"' showing total 26 results

Search Constraints

Start Over You searched for: Author "Assouline, David" Remove constraint Author: "Assouline, David"
26 results on '"Assouline, David"'

Search Results

1. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

2. Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

3. Sequential Chemotherapy with Mitoxantrone, Etoposide and Cytarabine for Previously Treated Acute Myeloid Leukemia: EMA 86 Regimen

8. Sequential Chemotherapy with Mitoxantrone, Etoposide and Cytarabine for Previously Treated Acute Myeloid Leukemia: EMA 86 Regimen

9. Leukemia following Hodgkin's disease

10. A Prognostic Score for Advanced Hodgkin's Disease

11. Additional file 2: of Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

12. Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

13. GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients

14. La proportion d'actifs tangible affecte-t-elle la performance boursière des IPO sur le marché Suisse ?

15. Final Results of the RiPAD+C Regimen Including Velcade In Front Line Therapy for Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group.

16. Interim Results of the RiPAD+C Regimen Including Velcade in Front Line Therapy for Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group.

19. HODGKIN'S DISEASE AFTER TRANSPLANTATION1

20. Rollout to the East accelerates: roadmap takes shape

24. « La concentration limite la diversité et le pluralisme ».

25. La proportion d'actifs tangible affecte-t-elle la performance boursière des IPO sur le marché Suisse ?

26. La proportion d'actifs tangible affecte-t-elle la performance boursière des IPO sur le marché Suisse ?

Catalog

Books, media, physical & digital resources